End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 AUD | -11.11% | +6.67% | -20.00% |
30/04 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
10/04 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.00% | 12.62M | C | ||
+32.36% | 695B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 361B | C+ | ||
+19.46% | 330B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 239B | B+ | ||
+6.68% | 204B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SNT Stock
- Ratings Syntara Limited